My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every time.
Start Research-backed Investing ...in less than a minute.
BSE: 539871 | NSE: THYROCARE | Hospital & Healthcare Services | Small Cap
1. Is Thyrocare Technologies Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Thyrocare Technologies Ltd is a good quality company.
2. Is Thyrocare Technologies Ltd undervalued or overvalued?
The key valuation ratios of Thyrocare Technologies Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
3. Is Thyrocare Technologies Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Thyrocare Technologies Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | 0% | 0% | 14.5% | 15.2% | 16% | 21.3% | 18.6% | 22.6% | 26.9% | 33.7% | - | ||
| Value Creation Index ⓘ | NA | NA | 0.0 | 0.1 | 0.1 | 0.5 | 0.3 | 0.6 | 0.9 | 1.4 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 0 | 0 | 183 | 241 | 304 | 356 | 403 | 434 | 495 | 589 | 521 | ||
| YoY Gr. Rt. % | - | NA | NA | 31.7% | 26.3% | 17.1% | 13.1% | 7.8% | 13.9% | 19.1% | - | ||
| Adj EPS ⓘ | 0 | 0 | 8.9 | 9.5 | 11.5 | 16.9 | 15.5 | 17 | 20.1 | 30 | 13.8 | ||
| YoY Gr. Rt. % | - | NA | NA | 6.9% | 21.1% | 46.8% | -8.6% | 9.9% | 18.4% | 49.3% | - | ||
| BVPS (₹) ⓘ | 0 | 0 | 54.5 | 67.6 | 75 | 82 | 81.7 | 68.7 | 80.3 | 98.9 | 97.1 | ||
| Adj Net Profit ⓘ | 0 | 0 | 45 | 51.1 | 62 | 90.9 | 81.6 | 89.8 | 106 | 159 | 73 | ||
| Cash Flow from Ops. ⓘ | 0 | 0 | 34.5 | 67.8 | 89.6 | 107 | 100 | 168 | 115 | 113 | - | ||
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | NA | 14.1% | 13.5% | 19.1% | ||||||||
| Adj EPS ⓘ | NA | 21.1% | 24.8% | 49.3% | ||||||||
| BVPS ⓘ | 0 | 5.7 | 6.6 | 23.2 | ||||||||
| Share Price | - | -6.5% | -4.9% | -45.6% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | 0 | 0 | 16.3 | 15.9 | 16 | 21.4 | 18.6 | 22.4 | 26.8 | 33.3 | 14.1 | |
| Op. Profit Mgn % ⓘ | 0 | 0 | 39.9 | 39.1 | 38.3 | 40.9 | 38.3 | 40 | 34.7 | 39.9 | 25.5 | |
| Net Profit Mgn % ⓘ | 0 | 0 | 24 | 21.2 | 20.4 | 25.5 | 20.1 | 20.5 | 21.8 | 27 | 14 | |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Working Cap Days ⓘ | 0 | 0 | 0 | 60 | 51 | 44 | 51 | 68 | 85 | 90 | 173 | |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 19 | 19 | 15 | 13 | 3 | 7 | 31 | 123 | |
Sales growth is growing at healthy rate in last 3 years 13.48%
Net Profit is growing at healthy rate in last 3 years 24.76%
Return on Equity has declined versus last 3 years average to 14.10%
Sales growth is not so good in last 4 quarters at -11.96%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 12.7 | 13.8 |
| TTM Sales (₹ Cr.) | 485 | 521 |
| BVPS (₹.) ⓘ | 95 | 97.1 |
| Reserves (₹ Cr.) ⓘ | 450 | 461 |
| P/BV ⓘ | 4.52 | 4.44 |
| PE ⓘ | 33.74 | 31.21 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 416.00 / 916.95 |
| All Time Low / High (₹) | 406.65 / 1465.90 |
| Market Cap (₹ Cr.) | 2,274 |
| Equity (₹ Cr.) | 52.9 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 58.5 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
Thyrocare Technologies Ltd. is India's first and most advanced Totally Automated Laboratory having its strong presence in several cities / towns in India and internationally. Thyrocare is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries. Thyrocare operates with a Centralized Processing Laboratory (CPL) in Mumbai - India for esoteric tests; and Regional Processing Laboratory in major metro cities of India and other parts of Asia. It has focus on strong technologies, strong brands and strong systems that enable all laboratories to give their clients the best of science and technology at an affordable cost. Thyrocare became one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations like ISO 9001-2000 rating as early as 2001, which is now escalated to ISO 9001:2008 and CAP (College of American Pathologists) certification in 2007.
Business area of the company
Thyrocare Technologies is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers cancer diagnosis and water testing through its brands Nueclear and Whaters, respectively.
Major events and milestones
Download APP
